AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MAYNE PHARMA GROUP LTD

7.230

+0.000

Volume:934.19K

Turnover:6.75M

Market Cap:587.41M

PE:-4.41

High:7.240

Open:7.230

Low:7.220

Close:7.230

Loading ...

Overview Company News Filings

Mayne Pharma Group Forecasts Growth in Fiscal H1 Revenues, Shares Rise Past 16%

MT Newswires Live

BUZZ-Australia's Mayne Pharma soars 13% on strong first-half earnings forecast

Mayne Pharma Group Ltd Sees 1H FY25 Underlying Ebitda1 of a$30 - a$32 Mln

THOMSON REUTERS

Mayne Pharma Group Ltd - Expects 1H FY25 Revenues to Be a$210 - a$215 Mln

THOMSON REUTERS

Mayne Pharma Group Ltd-Court Approval of Class Action Settlement

THOMSON REUTERS

Discover Alto Metals And 2 More Exciting Penny Stocks On The ASX

Simply Wall St.

BUZZ-Australia's Mayne Pharma plunges; no update on potential buyout interest

BRIEF-Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25

Mayne Pharma Group - Jul-Oct Revenue a$132.5 Mln

THOMSON REUTERS

Mayne Pharma Group Ltd - Expects Growth in Underlying Ebitda and Free Cash Flow in FY25

THOMSON REUTERS

Both retail investors who control a good portion of Mayne Pharma Group Limited (ASX:MYX) along with institutions must be dismayed after last week's 10.0% decrease

Simply Wall St.

Mayne Pharma Confirms Financial Adviser Appointment for Strategic Review

MT Newswires Live

BUZZ-Australia's Mayne Pharma jumps most since Aug. 23 on reports of pursuing takeover interest

BRIEF-Mayne Pharma Group Says It Confirms Jefferies Is Its Financial Adviser

Mayne Pharma - Jefferies Continues to Support Co in Assessing Its Strategies for Maximising Shareholder Value

THOMSON REUTERS

Mayne Pharma Group Ltd - Responds to Media Speculation

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MYX.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":7.23,"timestamp":1741151520000,"preClose":7.23,"halted":0,"volume":934189,"delay":0,"changeRate":0,"change":0,"floatShares":60876799,"shares":81245827,"eps":-1.638289,"lyrEps":-2.188306,"pbRate":1.32,"amount":6754978,"amplitude":0.002766,"volumeRatio":1.375295098315108,"dividePrice":0,"prevYearClose":4.97,"fiveDayClose":7.23,"twentyDayClose":4.6},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":60876799,"roa":"-0.50%","roe":"-23.75%","lyrEps":-2.188306,"volumeRatio":1.375295098315108,"shares":81245827,"dividePrice":0,"high":7.24,"amplitude":0.002766,"preClose":7.23,"low":7.22,"week52Low":3.74,"pbRate":"1.32","psRate":"1.42","week52High":7.46,"institutionHeld":0,"latestPrice":7.23,"eps":-1.638289,"divideRate":0,"volume":934189,"delay":0,"ttmEps":-1.638289,"open":7.23,"prevYearClose":4.97,"prevWeekClose":7.22,"prevMonthClose":7.22,"prevQuarterClose":4.97,"fiveDayClose":7.23,"twentyDayClose":4.6,"sixtyDayClose":5.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null},{"date":"2024-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708902000000,"name":null,"time":"","dateTimestamp":1708866000000,"actualEps":null},{"date":"2023-08-31","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693440000000,"name":null,"time":"","dateTimestamp":1693404000000,"actualEps":null},{"date":"2023-02-28","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677538800000,"name":null,"time":"","dateTimestamp":1677502800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510076240","title":"Mayne Pharma Group Forecasts Growth in Fiscal H1 Revenues, Shares Rise Past 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510076240","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510076240?lang=en_us&edition=fundamental","pubTime":"2025-02-10 08:18","pubTimestamp":1739146727,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  said it forecasts growth in its revenue for the fiscal first half ended Dec. 31, 2024, according to a Monday Australian bourse filing.The firm now expects H1 revenue to be AU$210 million to AU$215 million, reflecting a 12% to 14% rise in the same half-year period the previous year, the filing said.It also expects to report underlying earnings before interest, taxes, depreciation, and amortization during the period of AU$30 million to AU$32 million, representing an increase of 275% to 300% on the prior year period, driven by continued growth across the women's health portfolio, the filing said.Its cash and marketable securities came in at AU$124.9 million as of Dec. 31, 2024, a decline of AU$4.6 million compared to the balance as of Oct. 31, 2024.The firm's shares rose past 16% in early trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU"],"gpt_icon":0},{"id":"2510073040","title":"BUZZ-Australia's Mayne Pharma soars 13% on strong first-half earnings forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2510073040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510073040?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:43","pubTimestamp":1739144626,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma soars 13% on strong first-half earnings forecast** Shares of Mayne Pharma Group MYX.AX soar 13.3% to A$5.30, their highest level since December 3, 2024** Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index .AORD** Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million  and A$32 million, up to four-fold jump from last year's A$8 million** Revenue forecast between A$210 million and A$215 million, up to 14% growth** Co expects to see continued growth in 2H25** More than 112,000 shares change hands, vs the 30-day average of about 95,000 shares** MYX up 6.8% this year, including day's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nL4N3P004J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU"],"gpt_icon":0},{"id":"2510022774","title":"Mayne Pharma Group Ltd Sees 1H FY25 Underlying Ebitda1 of a$30 - a$32 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2510022774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510022774?lang=en_us&edition=fundamental","pubTime":"2025-02-10 05:32","pubTimestamp":1739136721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3P002U:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2510022772","title":"Mayne Pharma Group Ltd - Expects 1H FY25 Revenues to Be a$210 - a$215 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2510022772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510022772?lang=en_us&edition=fundamental","pubTime":"2025-02-10 05:32","pubTimestamp":1739136721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3P002U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MYX.AU","BK7508"],"gpt_icon":0},{"id":"2492169305","title":"Mayne Pharma Group Ltd-Court Approval of Class Action Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492169305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492169305?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:49","pubTimestamp":1734565794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUE7RD2G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2486067898","title":"Discover Alto Metals And 2 More Exciting Penny Stocks On The ASX","url":"https://stock-news.laohu8.com/highlight/detail?id=2486067898","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486067898?lang=en_us&edition=fundamental","pubTime":"2024-11-26 07:05","pubTimestamp":1732575908,"startTime":"0","endTime":"0","summary":"The Australian market is poised for a modest rise, buoyed by positive developments on Wall Street and reports of a potential Middle East ceasefire. Amidst these broader market movements, investors often look to smaller or newer companies for unique opportunities. Penny stocks, despite their somewhat outdated name, can still offer significant value when backed by strong financials. In this article, we explore three such penny stocks on the ASX that combine balance sheet strength with the potential for notable growth.Click here to see the full list of 1,046 stocks from our ASX Penny Stocks screener.Overview: Alto Metals Limited focuses on the exploration of gold properties in Western Australia and has a market cap of A$66.38 million.Explore historical data to track Alto Metals' performance over time in our past results report.Overview: Mayne Pharma Group Limited is a specialty pharmaceutical company that manufactures and sells branded and generic pharmaceutical products across Australia,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/q0yRN_h1fYD6SjjSkWx5lg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4afa9747177650711578ccd57242a6b7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/q0yRN_h1fYD6SjjSkWx5lg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4afa9747177650711578ccd57242a6b7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-alto-metals-2-more-230508692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0106831901.USD","MYX.AU","BK4585","BK4166","DFS","EVO.AU","LU1861220207.SGD","LBL.AU","BK7048","GTN.AU","BK7096","BK7132","BK7502","BK7131","LU1791807156.HKD","SHA.AU","ANG.AU","BK7045","BK7070","LU1668664300.SGD","BK7088","HLO.AU","BK7055","AME.AU","BK4588","XRF.AU","NGI.AU","BK7508","VLS.AU","XJO.AU","XKO.AU","XAO.AU","ATP.AU","LU2360107671.USD","BK7062","BK7104","LU1861217088.USD","EZZ.AU","BK7077"],"gpt_icon":0},{"id":"2485893884","title":"BUZZ-Australia's Mayne Pharma plunges; no update on potential buyout interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2485893884","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485893884?lang=en_us&edition=fundamental","pubTime":"2024-11-21 11:14","pubTimestamp":1732158872,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mayne Pharma plunges; no update on potential buyout interest** Shares of Australian drugmaker Mayne Pharma MYX.AX fall as much as 7.7% to A$4.11, their lowest since Aug. 23** Co provides no update on potential buyout interest, at its annual general meeting** MYX earlier in the month said Jefferies to assist co in terms of looking for a possible bidder ** Stock posts its biggest intraday pct fall since Nov. 13** Co says total revenue for the July-Oct period came in at A$132.5 mln , lower than the A$137 mln reported in the previous corresponding period** Two analysts covering the stock rate it \"buy\" or higher, their median PT is A$2.0 – LSEG data** Stock had fallen 32.7% this year, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL4N3MS05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2485910108","title":"BRIEF-Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25","url":"https://stock-news.laohu8.com/highlight/detail?id=2485910108","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485910108?lang=en_us&edition=fundamental","pubTime":"2024-11-21 09:13","pubTimestamp":1732151635,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Expects Growth In Underlying EBITDA And Free Cash Flow In Fy25Nov 21  - Mayne Pharma Group Ltd MYX.AX:EXPECTS GROWTH IN UNDERLYING EBITDA AND FREE CASH FLOW IN FY25FOR JULY-OCT UNDERLYING EBITDA OF A$14.7MJUL-OCT REVENUE A$132.5 MILLIONFurther company coverage: MYX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MR0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2485720841","title":"Mayne Pharma Group - Jul-Oct Revenue a$132.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2485720841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485720841?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:43","pubTimestamp":1732142625,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0WM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2485172288","title":"Mayne Pharma Group Ltd -  Expects Growth in Underlying Ebitda and Free Cash Flow in FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2485172288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485172288?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:43","pubTimestamp":1732142625,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2484456963","title":"Both retail investors who control a good portion of Mayne Pharma Group Limited (ASX:MYX) along with institutions must be dismayed after last week's 10.0% decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484456963","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484456963?lang=en_us&edition=fundamental","pubTime":"2024-11-19 04:14","pubTimestamp":1731960887,"startTime":"0","endTime":"0","summary":"Key Insights Mayne Pharma Group's significant retail investors ownership suggests that the key decisions are influenced...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-myx/mayne-pharma-group-shares/news/both-retail-investors-who-control-a-good-portion-of-mayne-ph-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2481120351","title":"Mayne Pharma Confirms Financial Adviser Appointment for Strategic Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2481120351","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481120351?lang=en_us&edition=fundamental","pubTime":"2024-11-08 14:54","pubTimestamp":1731048844,"startTime":"0","endTime":"0","summary":"Mayne Pharma  confirmed media speculation that it has appointed Jefferies Australia as its financial adviser, according to a Friday filing with the Australian bourse.Jefferies Australia will support the pharmaceutical firm in evaluating strategies to maximize shareholder value, the filing said.Mayne Pharma's shares closed up more than 15% Friday.Price : $5.10, Change: $+0.67, Percent Change: +15.12%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","LU1043141123.HKD","MYX.AU","LU0426412945.USD","XAO.AU","BK7508","XJO.AU","LU0345774631.USD","BK4125","XKO.AU","LU2238339852.HKD","BK7096","LU0426417589.USD","LU0994945656.USD"],"gpt_icon":0},{"id":"2481016967","title":"BUZZ-Australia's Mayne Pharma jumps most since Aug. 23 on reports of pursuing takeover interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2481016967","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481016967?lang=en_us&edition=fundamental","pubTime":"2024-11-08 09:30","pubTimestamp":1731029414,"startTime":"0","endTime":"0","summary":"** Mayne Pharma    climbs as much as 11.74% to A$4.950; biggest intraday pct gain since Aug. 23   ** MYX considering buyout with Jefferies looking for potential suitors, media report says   ** Co confirms Jefferies is its financial adviser and is assisting with strategies to maximize shareholder value   ** Mayne did not provide any further information to Reuters   ** Stock set for third consecutive sessions of gains; top gainer on ASX All Ordinaries index      ** MYX down 23.6% YTD ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XAO.AU","BK7096","XKO.AU","BK7508","MYX.AU","XJO.AU"],"gpt_icon":1},{"id":"2481816987","title":"BRIEF-Mayne Pharma Group Says It Confirms Jefferies Is Its Financial Adviser","url":"https://stock-news.laohu8.com/highlight/detail?id=2481816987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481816987?lang=en_us&edition=fundamental","pubTime":"2024-11-08 09:12","pubTimestamp":1731028345,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Says It Confirms Jefferies Is Its Financial AdviserNov 8 (Reuters) - Mayne Pharma Group Ltd MYX.AX:RESPONDS TO MEDIA SPECULATIONCONFIRMS THAT JEFFERIES IS ITS FINANCIAL ADVISE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nFWN3ME241:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MYX.AU"],"gpt_icon":0},{"id":"2481680121","title":"Mayne Pharma - Jefferies Continues to Support Co in Assessing Its Strategies for Maximising Shareholder Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2481680121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481680121?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:22","pubTimestamp":1731018123,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME241:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2481168067","title":"Mayne Pharma Group Ltd - Responds to Media Speculation","url":"https://stock-news.laohu8.com/highlight/detail?id=2481168067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481168067?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:22","pubTimestamp":1731018123,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME241:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":2,"totalSize":41}]}}